410 related articles for article (PubMed ID: 26053285)
1. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
Iaccarino L; Bartoloni E; Carli L; Ceccarelli F; Conti F; De Vita S; Ferraccioli G; Galeazzi M; Gatto M; Gerli R; Govoni M; Gremese E; Iuliano A; Mansutti E; Moroni G; Mosca M; Nalli C; Naretto C; Padovan M; Palma L; Raffiotta F; Roccatello D; Tincani A; Valesini G; Zen M; Doria A
Clin Exp Rheumatol; 2015; 33(4):449-56. PubMed ID: 26053285
[TBL] [Abstract][Full Text] [Related]
2. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].
Tsanian MÉ; Solov'ev SK; Torgashina AV; Aleksandrova EN; Radenska-Lopovok SG; Nikolaeva EV; Khrennikova IaB; Nasonov EL
Ter Arkh; 2014; 86(5):40-9. PubMed ID: 25026801
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
Trachana M; Koutsonikoli A; Farmaki E; Printza N; Tzimouli V; Papachristou F
Rheumatol Int; 2013 Mar; 33(3):809-13. PubMed ID: 22101555
[TBL] [Abstract][Full Text] [Related]
6. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.
Duxbury B; Combescure C; Chizzolini C
Lupus; 2013 Dec; 22(14):1489-503. PubMed ID: 24135078
[TBL] [Abstract][Full Text] [Related]
9. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.
Galarza-Maldonado C; Kourilovitch MR; Molineros JE; Cardiel MH; Zurita L; Soroka NF; Yagur VY; Doukh N; Cervera R
Autoimmun Rev; 2010 Dec; 10(2):108-11. PubMed ID: 20804861
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
[TBL] [Abstract][Full Text] [Related]
12. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
13. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).
Witt M; Grunke M; Proft F; Baeuerle M; Aringer M; Burmester G; Chehab G; Fiehn C; Fischer-Betz R; Fleck M; Freivogel K; Haubitz M; Kötter I; Lovric S; Metzler C; Rubberth-Roth A; Schwarting A; Specker C; Tony HP; Unger L; Wassenberg S; Dörner T; Schulze-Koops H;
Lupus; 2013 Oct; 22(11):1142-9. PubMed ID: 24057058
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.
Jónsdóttir T; Zickert A; Sundelin B; Henriksson EW; van Vollenhoven RF; Gunnarsson I
Rheumatology (Oxford); 2013 May; 52(5):847-55. PubMed ID: 23287364
[TBL] [Abstract][Full Text] [Related]
16. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.
Pinto LF; Velásquez CJ; Prieto C; Mestra L; Forero E; Márquez JD
Lupus; 2011 Oct; 20(11):1219-26. PubMed ID: 21784778
[TBL] [Abstract][Full Text] [Related]
17. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
18. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
19. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
20. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
Reis J; Aguiar F; Brito I
Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
